[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2019172714A1 - Composition alimentaire fonctionnelle pour améliorer la fonction musculaire et la mobilité et comprenant un extrait de camomille, et son procédé de préparation - Google Patents

Composition alimentaire fonctionnelle pour améliorer la fonction musculaire et la mobilité et comprenant un extrait de camomille, et son procédé de préparation Download PDF

Info

Publication number
WO2019172714A1
WO2019172714A1 PCT/KR2019/002740 KR2019002740W WO2019172714A1 WO 2019172714 A1 WO2019172714 A1 WO 2019172714A1 KR 2019002740 W KR2019002740 W KR 2019002740W WO 2019172714 A1 WO2019172714 A1 WO 2019172714A1
Authority
WO
WIPO (PCT)
Prior art keywords
muscle
food composition
functional food
function
chamomile extract
Prior art date
Application number
PCT/KR2019/002740
Other languages
English (en)
Korean (ko)
Inventor
김진학
장지환
금정호
권민선
최수영
김상우
황재관
Original Assignee
주식회사 뉴트리사이언스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 뉴트리사이언스 filed Critical 주식회사 뉴트리사이언스
Publication of WO2019172714A1 publication Critical patent/WO2019172714A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2300/00—Processes
    • A23V2300/14—Extraction

Definitions

  • the present invention relates to a muscle function and exercise-enhancing functional food composition comprising a chamomile extract and a method of manufacturing the same.
  • chamomile is Chamaemelum nobile, Matricaria It has the same scientific name as chamomilla, and the generic name Matricaria is Latin for 'matrix', which is derived from the effect of gynecological diseases. It is known to be mainly used in car, bathing, beauty, poultice, etc., and is effective for insect repellent, soothing, dysmenorrhea, pain relief, sweating, promoting digestion, and fatigue recovery.
  • the Chinese medicine refers to the effects of cardiovascular disease, cold, diarrhea, eczema, hemorrhagic cystitis, hemorrhoids, infant colic, soothing, vaginitis, wound healing.
  • the present inventors have completed the present invention by checking the effect of the composition containing the chamomile extract to improve muscle function and motor activity while studying the material originating from natural products.
  • An object of the present invention is to provide a functional food composition for strengthening muscle function and exercise performance.
  • a functional food composition for strengthening muscle function and exercise including chamomile extract.
  • the present invention may comprise more than 0% by weight to 100% by weight of chamomile extract based on the total weight of the composition.
  • composition for the prevention or amelioration of muscle-related diseases atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, myotonia, It can be used for the prevention or amelioration of one or more selected from the group consisting of amyotrophic lateral sclerosis, cachexia, sarcopenia.
  • a method for producing muscle function and strengthening functional food composition comprising the step of extracting chamomile in water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent. can do.
  • the method may include obtaining chamomile extract from chamomile by subcritical extraction, supercritical fluid extraction, or ultrahigh pressure extraction.
  • the functional food composition and method for enhancing muscle function and the production method according to the present invention it is possible to improve the production of factors related to energy metabolism and muscle production, and as a result can provide a composition that can improve the exercise ability and muscle function .
  • it can be applied to various fields such as food as a health functional composition.
  • 1 is a graph showing the activity of mTOR according to the embodiment.
  • FIG. 2 is a graph showing the activity of PPAR ⁇ according to the embodiment.
  • FIG. 3 is a graph showing the activity of PGC-1 ⁇ according to the embodiment.
  • Figure 4 is an electrophoresis picture showing the muscle protein degradation inhibitory activity according to the embodiment.
  • 5 is an electrophoretic photograph showing mitochondrial biosynthesis and muscle differentiation activity according to the embodiment.
  • muscle function and motor function enhancement 'means improving the activity of mTOR, PPAR ⁇ and PGC-1 ⁇ , inhibiting the degradation of muscle protein, promoting the biosynthesis of mitochondria, and promoting muscle differentiation. .
  • inhibition of muscle protein degradation may be confirmed by the reduction of mRNA expression of atrogin-1 and MuRF-1.
  • mitochondrial biosynthesis promotion and muscle differentiation promoting activity can be confirmed that the mRNA expression of myogenin, NRF1, Tfam is increased.
  • muscle function and exercise ability by strengthening muscle function and exercise ability, it is possible to prevent, treat and improve muscle-related diseases. Prevention, treatment and improvement of muscle related diseases can be confirmed by expression of muscle and exercise related factors such as mTOR, PPAR ⁇ and PGC-1 ⁇ .
  • Muscle-related diseases may include diseases due to decreased muscle function, muscle wasting, muscle degeneration and the like. Specifically, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myasthenia, myotonia, amyotrophic lateral sclerosis, cachexia Can prevent, treat and ameliorate diseases such as sarcopenia.
  • the muscle function and exercise enhancing functional food composition according to the present invention includes chamomile extract.
  • the present invention may comprise more than 0% to 100% by weight of chamomile extract, for example 1 to 100% by weight, for example 20 to 70% by weight relative to the total weight of the composition.
  • the muscle function and motor function-enhancing functional food composition may be prepared by a method comprising obtaining chamomile extract with water, an organic solvent having 1 to 6 carbon atoms, or a mixture thereof as a solvent.
  • the organic solvent having 1 to 6 carbon atoms may include methanol, ethanol, ethyl acetate, hexane, and the like.
  • the composition according to the invention may be prepared by a method comprising the step of extracting alcohol or hot water extracted for chamomile.
  • 10-95%, for example 20-80%, for example 50% alcohol may be used in the alcohol extraction step.
  • it may include the step of extracting the alcohol by adding 2 to 20 times the volume of the extraction target. It may also be extracted for example for 0.5 to 10 hours, for example 2 to 5 hours, for example at 4 to 80 ° C, for example 20 to 70 ° C, for example 40 to 60 ° C. Can be.
  • the hydrothermal extraction step may include extracting by adding 2 to 20 times the volume of the extraction target volume of water. It can also be extracted for example for 0.5 to 12 hours, for example 2 to 6 hours, for example at 4 to 121 ° C, for example 50 to 121 ° C, for example 80 to 121 ° C. Can be.
  • the muscle function and exercise enhancing functional food composition may be prepared by a method comprising obtaining chamomile extract from chamomile using subcritical extraction, supercritical fluid extraction or ultrahigh pressure extraction.
  • Chamomile extract was obtained in the same manner as in Example 2 except that methanol was used.
  • Chamomile extract was obtained in the same manner as in Example 2, except that ethyl acetate was used.
  • Chamomile extract was obtained in the same manner as in Example 2 except that hexane was used.
  • Chamomile 18%, ethanol 76mL was put in a polyethylene pack and sealed and extracted using an ultrahigh pressure extractor (Frescal MFP-7000; Mitsubishi Heavy Industries, Tokyo, Japan).
  • the extraction pressure was set to 320MPa and the extraction time was 5 minutes as the ultrahigh pressure extraction condition.
  • the extracted sample was filtered and concentrated to remove the extraction solvent, and lyophilized to obtain a chamomile extract.
  • Chamomile was charged to a sample cartridge and extracted using a supercritical extractor (SFX 3560, Isco Inc., Lincoln, NE, USA).
  • Supercritical fluid extraction conditions were set to extraction pressure 20MPa, extraction temperature 60 °C, flow rate of supercritical carbon dioxide 60mL / min, extraction time 60 minutes.
  • the pressure of the extractor was lowered to release the supercritical fluid state to obtain a chamomile extract.
  • mTOR activity for each extract according to Example 1 was evaluated.
  • mTOR is a protein that plays a role in regulating the mechanism of muscle protein synthesis, and can confirm the improvement of muscle mass by confirming the activity of mTOR.
  • a muscle cell master L6 cells 110% fetal calf serum 2 ⁇ 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated.
  • DMEM Hyclone
  • HS horse serum
  • the extract prepared in Example 1 was dissolved in DMEM medium containing 50ng / mL of TNF- ⁇ at a concentration of 100 or 200ug / mL, and then treated to cells. After 6 hours, total RNA was isolated using TRIzol reagent (Takara, Osaka, Japan). Total RNA isolated was quantified using NanoDrop 1000; Thermo Fisher Scientific Inc., Waltham, Mass., USA. The results are shown in Table 1.
  • COS7 cells (ATCC) were placed in DMEM medium containing 10% FBS (Gibco) in a 24-well plate at 1 ⁇ 10 5 cells / mL.
  • FBS FBS
  • Lipofector EXT (Aptabio) was used to induce PPAR ⁇ transformation to identify anti-inflammatory effects.
  • each extract was added to the cells together at a concentration of 10 ⁇ g / mL. 24 hours treatment.
  • luciferase activity was evaluated using luciferase assay kit (Promega).
  • PPAR ⁇ is a protein that may be associated with cell differentiation in adipose tissue and sugar production in liver tissue. As a result, PPAR ⁇ may be confirmed to improve motor performance by confirming the activity of PPAR ⁇ . The results are shown in Table 2.
  • COS7 cells (ATCC) were placed in DMEM medium containing 10% FBS (Gibco) to 1 ⁇ 10 5 cells / mL in 24-well plates.
  • FBS peroxisome proliferator-activated receptor gamma coactivator-1 alpha
  • PGC-1 ⁇ peroxisome proliferator-activated receptor gamma coactivator-1 alpha
  • Each extract was treated with cells at a concentration of 10 ⁇ g / mL for 24 hours.
  • luciferase activity was evaluated using luciferase assay kit (Promega).
  • PGC-1 ⁇ is a protein related to glycemic regulation and mitochondrial function replication, which can confirm the improvement of exercise ability by confirming the activity of PGC-1 ⁇ .
  • the results are shown in Table 3.
  • Atrogin-1 is a muscle breakdown protein that is activated when muscle is lost
  • MuRF1 is a muscle degrading enzyme protein
  • ⁇ -actin is a protein that makes up muscle, which causes muscle contraction and relaxation with myosin.
  • L6 cells 110% fetal bovine serum (FBS; Hyclone, Logan, UT , USA) Dulbecco's modified Eagle's media (DMEM; Hyclone) is contained 2 ⁇ 10 in 6-well plates with 5 cell / After inoculation to mL was incubated. When the cell density is about 80-85%, the medium in the wells is removed and exchanged for DMEM (Hyclone) containing 2% horse serum (HS; Hyclone) to convert L6 cells into myotubes. Differentiated. Once every two days, the cells were replaced with fresh medium for a total of six days of differentiation.
  • FBS fetal bovine serum
  • DMEM Dulbecco's modified Eagle's media
  • RNA 16 uL RNA was quantified and mixed with Reverse Transcriptase Premix (ELPIS-Biotech) using a PCR machine (Gene Amp PCR System 2700; Applied Biosystems, Foster City, CA, USA) at 42 ° C, 55 minutes, 70 CDNA was synthesized at 15 ° C. for 15 minutes.
  • PCR samples were prepared by mixing 4 uL of the cDNA, specific primer pairs (Bioneer, Deajeon, Korea), and PCR premix (ELPIS-Biotech) below in the synthesized cDNA, and then, at 95 ° C for 30 seconds and at 60 ° C. PCR was performed by repeating 30 minutes for 1 minute at 72 ° C.
  • the cDNA amplified by PCR was electrophoresed with 1.5% agarose gel, and cDNA bands were identified using a G; BOX EF imaging system (Syngene, Cambridge, UK). The used sequences are shown in Table 4, and the results are shown in FIG.
  • Example 1 In order to confirm the muscle mitochondrial biosynthesis promoting and muscle differentiation promoting activity of Example 1, the expression of myogenin, NRF1 and Tfam was confirmed. Myogenin controls differentiation and maturation into myotubes, NRF1 is involved in mitochondrial protein production, and Tfam is involved in mitochondrial DNA transcription.
  • a muscle cell master L6 cells 110% fetal calf serum 2 ⁇ 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated. When the cell density reached about 80 to 85%, the medium in the well was removed and the chamomile extract prepared in Example 1 was added to DMEM (Hyclone) containing 2% HS at a concentration of 100 or 200 ug / mL. After thawing, the cells were treated to induce differentiation into root canal cells.
  • ATCC fetal calf serum 2 ⁇ 10 5 to 6-well plate with (FBS;; Hyclone, Logan, UT, USA) Dulbecco's modified Eagle's media (Hyclone DMEM) is contained After inoculation to cell / mL was incubated. When the cell density reached about 80
  • the cDNA amplified by PCR was electrophoresed with 1.5% agarose gel, and cDNA bands were identified using a G; BOX EF imaging system (Syngene, Cambridge, UK). The used sequences are shown in Table 5, and the results are shown in FIG.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Health & Medical Sciences (AREA)
  • Nutrition Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne une composition alimentaire fonctionnelle pour améliorer la fonction musculaire et la mobilité et son procédé de préparation. Selon la présente invention, l'invention concerne une composition qui permet une génération accrue de facteurs associés à la myogenèse et au métabolisme énergétique et améliore ainsi la mobilité et la fonction musculaire. Plus particulièrement, la synthèse de mitochondries et de cellules musculaires est accrue et l'atrophie musculaire est inhibée, et ainsi les effets d'exercice musculaire peuvent être accrus et la fatigue est réduite. La composition peut être appliquée sous la forme d'une composition de fonction de santé à divers domaines tels que des aliments.
PCT/KR2019/002740 2018-03-09 2019-03-08 Composition alimentaire fonctionnelle pour améliorer la fonction musculaire et la mobilité et comprenant un extrait de camomille, et son procédé de préparation WO2019172714A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180027742A KR102066388B1 (ko) 2018-03-09 2018-03-09 캐모마일 추출물을 포함하는 근기능 및 운동능 강화 기능성 식품 조성물 및 그 제조방법
KR10-2018-0027742 2018-03-09

Publications (1)

Publication Number Publication Date
WO2019172714A1 true WO2019172714A1 (fr) 2019-09-12

Family

ID=67846781

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/002740 WO2019172714A1 (fr) 2018-03-09 2019-03-08 Composition alimentaire fonctionnelle pour améliorer la fonction musculaire et la mobilité et comprenant un extrait de camomille, et son procédé de préparation

Country Status (2)

Country Link
KR (1) KR102066388B1 (fr)
WO (1) WO2019172714A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102651910B1 (ko) 2021-03-08 2024-03-27 주식회사 에치와이 락토바실러스 플란타럼 hy7715를 포함하는 근육질환 예방 또는 개선용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920010389B1 (ko) * 1984-03-16 1992-11-27 아스타 메디카 아크티엔게젤샤프트 플라본이 풍부한 카모밀라 추출물의 제조방법
JP2010534697A (ja) * 2007-07-31 2010-11-11 フレセニウス・カビ・ドイツチユラント・ゲーエムベーハー 悪液質予防補助食品
US20150283189A1 (en) * 2014-04-04 2015-10-08 Biologische Heilmittel Heel Gmbh Medicament for treating muscle and skeletal diseases
KR20170044737A (ko) * 2014-08-27 2017-04-25 에스더블유엠 룩셈부르크 에스.에이.알.엘. 압출 또는 성형 공정을 사용하는 재구성된 식물 물질을 제조하는 방법, 및 이로부터 얻어진 생성물
CN107308407A (zh) * 2017-06-29 2017-11-03 芜湖凌梦电子商务有限公司 一种有效缓解肌肉痉挛和关节酸痛的复合精油

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920010389B1 (ko) * 1984-03-16 1992-11-27 아스타 메디카 아크티엔게젤샤프트 플라본이 풍부한 카모밀라 추출물의 제조방법
JP2010534697A (ja) * 2007-07-31 2010-11-11 フレセニウス・カビ・ドイツチユラント・ゲーエムベーハー 悪液質予防補助食品
US20150283189A1 (en) * 2014-04-04 2015-10-08 Biologische Heilmittel Heel Gmbh Medicament for treating muscle and skeletal diseases
KR20170044737A (ko) * 2014-08-27 2017-04-25 에스더블유엠 룩셈부르크 에스.에이.알.엘. 압출 또는 성형 공정을 사용하는 재구성된 식물 물질을 제조하는 방법, 및 이로부터 얻어진 생성물
CN107308407A (zh) * 2017-06-29 2017-11-03 芜湖凌梦电子商务有限公司 一种有效缓解肌肉痉挛和关节酸痛的复合精油

Also Published As

Publication number Publication date
KR102066388B1 (ko) 2020-01-15
KR20190107249A (ko) 2019-09-19

Similar Documents

Publication Publication Date Title
WO2019172712A1 (fr) Composition alimentaire fonctionnelle pour améliorer la fonction musculaire et la mobilité et comprenant un extrait de feuille de lotus, et son procédé de préparation
Recio et al. Immunmodulatory and antiproliferative properties of Rhodiola species
WO2021040371A1 (fr) Composition anti-inflammatoire
WO2021153876A1 (fr) Procédé de différenciation de cellules souches mésenchymateuses dérivées du tissu adipeux humain en cellules de papille dermique
WO2018043864A1 (fr) Souche de leuconostoc holzapfelii ayant pour effets de prévenir la perte des cheveux, de favoriser la pousse des cheveux ou d'améliorer la fonction sexuelle, et composition la comprenant
WO2021261632A1 (fr) Nouvelle souche de faecalibacterium prausnitzii eb-fpdk11 et utilisation associée
Cui et al. An oleanolic acid derivative reduces denervation-induced muscle atrophy via activation of CNTF-mediated JAK2/STAT3 signaling pathway
WO2019059606A1 (fr) Composition contenant un extrait d'amomum villosum pour la prévention, la réduction ou le traitement de l'obésité
WO2019172714A1 (fr) Composition alimentaire fonctionnelle pour améliorer la fonction musculaire et la mobilité et comprenant un extrait de camomille, et son procédé de préparation
WO2017030383A2 (fr) Composition pharmaceutique pour prévenir ou traiter une dystrophie musculaire, contenant du bakuchiol en tant que principe actif
WO2017086744A1 (fr) Composition pharmaceutique pour prévenir et traiter un cancer ou des métastases cancéreuses, contenant la protéine pstl1 en tant que substance active
EP2774617B1 (fr) Composition médicale contenant un extrait de stauntonia hexaphylla
WO2021141237A1 (fr) Composition de renforcement de fonction de cellule souche
WO2022240243A1 (fr) Composition de blanchiment de la peau contenant des nanovésicules
WO2023158024A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'une maladie intestinale inflammatoire comprenant de l'isodon excisus (max), un composé dérivé du kudo en tant que principe actif
Cui et al. Osteon Myospalacem Baileyi attenuates osteoclast differentiation through RANKL induced NFAT pathways
KR102383026B1 (ko) 관중 유래 화합물 또는 이의 유도체를 포함하는 코로나바이러스 감염 예방 및 치료용 약학 조성물
WO2021162463A1 (fr) Composition pour prévenir, traiter et soulager la dermatite atopique, comprenant un composé conjugué de flavone-resvératrol
WO2010058936A2 (fr) Composition externe pour la peau contenant des dérivés d'ortho-dihydroxyisoflavone et pouvant empêcher l'hyperprolifération épidermique et atténuer les affections cutanées inflammatoires
WO2021261631A1 (fr) Nouvelle souche de picalibacterium prosnich eb-fpdk9 et utilisations associées
WO2022239916A1 (fr) Nouvelle souche de bifidobacterium longum et son utilisation
Liang et al. Effect of puerarin on TIMP3, MMP-9 expression and methylation in chondrocytes of rat osteoarthritis
WO2018056585A1 (fr) Composition de renforcement de la fonction de barrière cutanée comprenant un matériau favorisant l'expression de card18, et procédé de criblage de matériau favorisant l'expression de card18
WO2024147560A1 (fr) Composition d'immunothérapie anticancéreuse comprenant un extrait de toxicodendron vernicifluum et des cellules tueuses induites par les cytokines
US20090136600A1 (en) Method for alleviating chemotherapy side effects using extract of dioscorea sp.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19763728

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19763728

Country of ref document: EP

Kind code of ref document: A1